Abdelghani Omari

Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany.

Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding private company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012.

Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The private company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU.